STOCK TITAN

Achilles Therapeutics Plc - ACHL STOCK NEWS

Welcome to our dedicated news page for Achilles Therapeutics Plc (Ticker: ACHL), a resource for investors and traders seeking the latest updates and insights on Achilles Therapeutics Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Achilles Therapeutics Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Achilles Therapeutics Plc's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.5%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.35%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.16%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.13%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.43%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
Achilles Therapeutics Plc

Nasdaq:ACHL

ACHL Rankings

ACHL Stock Data

33.29M
21.54M
5.88%
50.86%
0.19%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United Kingdom
245 Hammersmith Road

About ACHL

achilles therapeutics’ mission is to develop next-generation, patient-specific therapies that harness the immune system to destroy cancer cells. the therapies will target truncal (also known as clonal) tumour neo-antigens, unique flags to the immune system present on the surface of every cancer cell. these truncal neo-antigens are created early in the cancer’s evolution and present on all cancer cells in an individual patient’s tumour but not on healthy cells, so could allow scientists to target and destroy tumours without harming healthy tissues. achilles therapeutics brings together four scientific founders with world leading expertise in the understanding of cancer evolution, bioinformatics and the development of immunotherapies.